Table 3 Comparison of antibiotic susceptibility rates between the non-ESBL and ESBL groups
Antibiotics | Non-ESBL group | ESBL group | p-value |
|---|---|---|---|
(n = 189) | (n = 22) | ||
Penicillins | |||
Ampicillin | 44/131 (33.6) | 0/18 (0.0) | 0.003 |
Piperacillin | 40/103 (38.8) | 0/11 (0.0) | 0.008 |
Cephalosporins | |||
Cefoxitin | 127/130 (97.7) | 16/18 (88.9) | 0.112 |
Cefotaxime | 142/144 (98.6) | 2/19 (10.5) | <0.001 |
Caftazidime | 185/189 (97.9) | 10/22 (45.5) | <0.001 |
Cefepime | 186/189 (98.4) | 10/22 (45.5) | <0.001 |
β-lactam/β-latamase inhibitor combinations | |||
Amoxicillin/clavulanate | 107/131 (81.7) | 12/18 (66.7) | 0.205 |
Piperacillin/tazobactam | 177/187 (94.7) | 18/21 (85.7) | 0.131 |
Carbapenems | |||
Imipenem | 189/189 (100.0) | 22/22 (100.0) | NA |
Meropenem | 189/189 (100.0) | 22/22 (100.0) | NA |
Aminoglycosides | |||
Gentamicin | 158/188 (84.0) | 16/22 (72.7) | 0.228 |
Tobramycin | 87/102 (85.3) | 9/11 (81.8) | 0.670 |
Amikacin | 188/189 (99.5) | 22/22 (100.0) | 1.000 |
Isepamicin | 58/58 (100.0) | 4/4 (100.0) | NA |
Fluoroquinolones | |||
Ciprofloxacin | 128/145 (88.3) | 8/15 (53.3) | 0.002 |
Levofloxacin | 42/44 (95.5) | 5/7 (71.4) | 0.086 |
Others | |||
Trimethoprim/sulfamethoxazole | 137/188 (72.9) | 13/22 (59.1) | 0.176 |
Colistin | 58/58 (100.0) | 4/4 (100.0) | NA |
Minocycline | 47/58 (81.0) | 4/4 (100.0) | 1.000 |